CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

SIGA Technologies Q3 net loss narrows on international sales

By Reuters News


Overview

  • U.S. pharmaceutical firm's Q3 revenue and product sales declined year-over-year

  • Company posted Q3 net loss, narrowing from year-ago period

  • Awarded $15 mln oral TPOXX contract from Canadian Department of National Defence in October


Outlook

  • Company is actively pursuing new international government contracts to diversify its customer base

  • SIGA continues to seek a new TPOXX procurement contract with the U.S. Government

  • Canadian Department of National Defence contract includes firm commitments of about $9 mln over three years


Result Drivers

  • INTERNATIONAL SALES - Co delivered $13 mln of oral TPOXX to two international customers in first nine months

  • U.S. CONTRACT FULFILLMENT - Co completed final IV TPOXX deliveries to U.S. Strategic National Stockpile under 19C contract


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

$2.9 mln


Analyst Coverage

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago


Reuters Recommended Reads

  • Nov 9 - Tonix Pharmaceuticals Q3 revenue jumps on TONMYA sales

  • Nov 9 - Ocular Therapeutix Q3 loss widens as product revenue drops, costs rise

  • Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.